par Vermeulen, Françoise 
;Verscheure, Virginie ;Damis, Eliane;Vermeylen, Danièle ;Leloux, Gaëlle ;Dirix, Violette ;Locht, Camille ;Mascart, Françoise
Référence Clinical and vaccine immunology, 17, 2, page (258-262)
Publication Publié, 2010-02
;Verscheure, Virginie ;Damis, Eliane;Vermeylen, Danièle ;Leloux, Gaëlle ;Dirix, Violette ;Locht, Camille ;Mascart, Françoise Référence Clinical and vaccine immunology, 17, 2, page (258-262)
Publication Publié, 2010-02
Article révisé par les pairs
| Résumé : | Based on studies reporting specific antibody titers, it is recommended to vaccinate preterm infants against Bordetella pertussis according to their chronological age. However, as specific T-cell responses also are involved in the protection against B. pertussis, we have determined whether highly preterm infants (<31 weeks) are able to mount these immune responses during vaccination. Forty-eight premature infants were vaccinated at 2, 3, and 4 months of their chronological age with an acellular (Pa; n = 24) or a whole-cell (Pw; n = 24) tetravalent diphtheria-tetanus-pertussis-polio vaccine, and blood samples were collected at 2, 3, and 6 months of age. Most of the Pa- and Pw-vaccinated infants developed at 3 or 6 months of age a gamma interferon (IFN-gamma) response to the B. pertussis antigens, accompanied by an interleukin-5 (IL-5) and IL-13 secretion for the Pa-vaccinated infants. No association was found between a very low infant birth weight, the occurrence of severe infections, and corticosteroid treatment or the administration of gammaglobulins with a low level of antigen-induced IFN-gamma secretion. We conclude that like full-term infants, most preterm infants are able to mount a specific cellular immune response to the administration of the first doses of an acellular or a whole-cell pertussis vaccine. |
